
Kluwer Patent Blog

United Kingdom: Actavis UK Limited and others v. Eli Lilly and Company, High Court of Justice of England and Wales, Chancery Division, Patents Court, HC12E02962, 12 February 2016

Aida Tohala (Bristows) · Monday, August 29th, 2016

The High Court has granted the Claimants' request for declarations of non-infringement ("DNIs") regarding several national designations of the Defendant's European Patent for a pemetrexed disodium and vitamin B12 combination in respect of reconstitution of the Claimants' lyophilised pemetrexed product when reconstituted in dextrose solution. The issues in this case were remitted by the Court of Appeal in its June 2015 decision overturning the grant of DNIs regarding the same European Patent, which was based on reconstitution of Actavis' pemetrexed product in saline (*Actavis UK Limited v Eli Lilly & Company* [2015] EWCA Civ 555).


A [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2021 Future Ready Lawyer survey** showed that 81% of the law firms expect to view technology as an important investment in their future ability to thrive. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.



Kluwer IP Law

 Wolters Kluwer

This entry was posted on Monday, August 29th, 2016 at 11:17 am and is filed under [Case Law, United Kingdom](#)

You can follow any responses to this entry through the [Comments \(RSS\) feed](#). Both comments and pings are currently closed.